The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Prothrombin Complex Concentrate Market By The End Of 2030?
The prothrombin complex concentrate market size has observed substantial growth in recent years. It is forecast to increase from $1.38 billion in 2025 to $1.48 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. This historical growth can be attributed to several factors, including the rising prevalence of coagulation disorders, the expansion of emergency care infrastructure, the increasing availability of plasma-derived therapies, growing surgical procedure volumes, and the broadening use of anticoagulant medications.
The prothrombin complex concentrate market is anticipated to experience substantial expansion over the coming years. Its valuation is projected to reach $1.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. This projected growth during the forecast timeframe stems from a heightened need for rapid-onset coagulation treatments, escalating investments in developing recombinant factors, an increase in trauma care infrastructure, a greater emphasis on ensuring patient safety during anticoagulant administration, and the wider implementation of standardized bleeding guidelines. Key trends anticipated for the forecast period encompass the wider acceptance of four-factor pcc products, a surge in the application of pcc for swift anticoagulant reversal, an expanding requirement for emergency bleeding control solutions, the broadening availability of recombinant coagulation products, and a stronger emphasis on quick-acting hemostatic treatments.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp
What Drivers Are Shaping The Future Growth Of The Prothrombin Complex Concentrate Market?
The expanding occurrence of bleeding disorders is anticipated to boost the prothrombin complex concentrate market’s expansion in the future. These disorders are health issues where blood fails to coagulate correctly, resulting in excessive blood loss because of absent or defective clotting factors or platelets. The rise in bleeding disorders is primarily attributed to the growing incidence of genetic ailments like hemophilia, more cases of liver disease, increased consumption of anticoagulant drugs, and a greater occurrence of vitamin K deficiencies. Prothrombin complex concentrate aids in managing bleeding disorders by quickly restoring clotting factors, vital for proper blood coagulation and stopping bleeding. For example, an October 2024 report from the World Federation of Hemophilia, a Canada-based non-profit, indicated that in 2023, 179,703 cases of hemophilia A were recorded. Of these, 162,040 cases (90%) were male, 6,990 cases were female, and 10,673 cases (6%) lacked specified sex information. Consequently, the expanding prevalence of bleeding disorders is fueling the expansion of the prothrombin complex concentrate market.
Which Segment Classifications Shape The Prothrombin Complex Concentrate Market?
The prothrombin complex concentrate market covered in this report is segmented –
1) By Product: 3-Factor Prothrombin Complex Concentrates, 4-Factor Prothrombin Complex Concentrates, Other Products
2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B), Trauma, Life-Threatening Coagulopathy With Acute Bleeding, Warfarin-Associated Acute, Life-Threatening Bleeding, Non-Warfarin Anticoagulant Reversal With Acute Bleeding
3) By Route Of Administration: Intravenous, Intravenous Infusion Variants, Intravenous Bolus Administration
4) By End-Use: Hospital And Ambulatory Surgical Centers, Specialty Clinics, Other End Users
Subsegments:
1) By 3-Factor PCC Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC), High-Dose 3-Factor Prothrombin Complex Concentrates (PCC), Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)
2) By 4-Factor PCC Typ: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC), High-Dose 4-Factor Prothrombin Complex Concentrates (PCC), Activated 4-Factor Prothrombin Complex Concentrates (PCC)
3) By Other Products: Recombinant Coagulation Factor Complexes, Plasma-Derived Coagulation Factor Complexes, Combination Therapy Products
Which Upcoming Trends Are Expected To Influence The Prothrombin Complex Concentrate Market?
Leading companies in the prothrombin complex concentrate market are developing advanced formulations, such as lyophilized powder, to improve stability, optimize storage, and simplify administration. This lyophilized powder is a freeze-dried formulation designed to remove water, thereby increasing shelf life and maintaining potency. Consequently, this enables superior storage conditions and rapid reconstitution for emergency situations. For instance, in July 2023, Octapharma USA Inc., a US-based biotechnology company, obtained FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC), intended for urgent warfarin reversal during surgeries and invasive procedures. This approval was granted following the LEX-209 trial, which recorded a 94.6% hemostatic efficacy, confirming its effectiveness comparable to Kcentra. This significant advancement emphasizes the industry’s commitment to enhancing coagulation therapies to improve patient outcomes in critical care environments.
Which Companies Are Expanding Their Footprint In The Prothrombin Complex Concentrate Market?
Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Takeda Pharmaceutical Company Limited, CSL Behring GmbH, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd BPL, Prothya Biosolutions B.V., China Biologic Products Holdings Inc., Intas Pharmaceuticals Ltd, Biotest AG, Octapharma Plasma, Kamada Ltd, SK Plasma Co. Ltd, Reliance Life Sciences, Bharat Serums And Vaccines Limited
Read the full prothrombin complex concentrate market report here:
Which Geographic Regions Are Influencing Demand In The Prothrombin Complex Concentrate Market?
North America was the largest region in the prothrombin complex concentrate market in 2025. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Prothrombin Complex Concentrate Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp
Browse Through More Reports Similar to the Global Prothrombin Complex Concentrate Market 2026, By The Business Research Company
Proteomics Global Market Report
https://www.thebusinessresearchcompany.com/report/proteomics-global-market-report
Serine Proteases Global Market Report
https://www.thebusinessresearchcompany.com/report/serine-proteases-global-market-report
Pruritus Therapeutic Global Market Report
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model